News headlines about Nektar Therapeutics (NASDAQ:NKTR) have been trending somewhat positive on Monday, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Nektar Therapeutics earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.7431518420369 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news articles that may have effected Accern’s rankings:
- WHY YOU SHOULD NOT GIVE UP ON ARCHER: Nektar Therapeutics, (NASDAQ: NKTR) (stocksnewspro.com)
- Is It The Right Time To Buy? Nektar Therapeutics (NKTR) (nysestocks.review)
- Hold Recommendation?: Nektar Therapeutics (NKTR) (nasdaqplace.com)
- Nektar Therapeutics (NKTR) 4.00% away from 20 SMA (nasdaqchronicle.com)
- Long-Term Trade Secrets – Nektar Therapeutics (NASDAQ:NKTR) (nasdaqjournal.com)
Shares of Nektar Therapeutics traded down $1.83, hitting $83.47, on Monday, Marketbeat reports. 1,617,098 shares of the company were exchanged, compared to its average volume of 2,930,150. Nektar Therapeutics has a one year low of $17.51 and a one year high of $111.36. The company has a debt-to-equity ratio of 4.21, a quick ratio of 4.03 and a current ratio of 4.16. The company has a market cap of $14.62 billion, a price-to-earnings ratio of -151.76 and a beta of 1.79.
A number of research analysts have weighed in on NKTR shares. Mizuho boosted their target price on shares of Nektar Therapeutics from $45.00 to $89.00 and gave the stock a “buy” rating in a research report on Monday, January 22nd. BidaskClub lowered shares of Nektar Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 8th. Zacks Investment Research raised shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, February 21st. Canaccord Genuity boosted their target price on shares of Nektar Therapeutics to $94.00 and gave the stock a “buy” rating in a research report on Friday, March 2nd. Finally, Jefferies Group boosted their target price on shares of Nektar Therapeutics to $103.00 and gave the stock a “buy” rating in a research report on Friday, March 2nd. Three analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $79.50.
In other news, Director Christopher A. Kuebler sold 40,000 shares of the business’s stock in a transaction dated Wednesday, March 7th. The shares were sold at an average price of $97.60, for a total transaction of $3,904,000.00. Following the transaction, the director now owns 43,100 shares in the company, valued at approximately $4,206,560. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Stephen K. Doberstein sold 160,000 shares of the business’s stock in a transaction dated Monday, April 9th. The stock was sold at an average price of $93.06, for a total transaction of $14,889,600.00. Following the transaction, the senior vice president now owns 127,394 shares in the company, valued at approximately $11,855,285.64. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 827,019 shares of company stock worth $75,562,898. Insiders own 5.44% of the company’s stock.
About Nektar Therapeutics
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain based on its PEGylation and polymer conjugate technology platforms in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.